Study: Femara reduces risk of breast cancer recurrence

03/10/2008 | MSNBC

Researchers found that taking Femara, Novartis AG's breast cancer pill, up to seven years after finishing tamoxifen therapy lowered the risk of breast cancer recurrence in post-menopausal patients by 63%. The drug, an aromatase inhibitor, slashed metastasis risk by 61% and lowered the risk of tumor growth in the unaffected breast by more than 80% percent, according to the study.

View Full Article in:

MSNBC

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN